stockrow
Saturday 7 November 2026
Export PHAR’s income statement to Excel — free account
Pharming Group N.V. Sponsored ADR
PHAR Healthcare Biotechnology
Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024.
- Revenue
- +20.9%
- EPS
- +190.9%
- Free cash flow
- +0.42%
- Total debt
- +1.61%
Quarter to September 2026, against a year earlier
12.32
0.02
+0.16%
Follow PHAR
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 5 | 6 | 6 | 2 | 3 | 5 |
P/E ratio |
80.75 | 80.75 | 80.75 | 80.75 | 77.31 | 63.00 | 60.74 | 0.00 | 0.00 | 441.75 |
Altman Z-Score |
— | — | — | — | 3.12 | 1.95 | 2.34 | 2.15 | 2.59 | 3.88 |
P/S ratio |
52.19 | 52.19 | 52.19 | 52.19 | 44.99 | 29.41 | 3.65 | 3.08 | 2.27 | 3.24 |
Altman Z″-Score (non-manufacturers) |
(7.55) | — | — | (1.44) | 2.66 | 2.33 | 2.65 | 2.37 | 2.26 | 2.28 |
P/FCF ratio |
57.90 | 57.90 | 57.90 | 57.90 | 79.97 | 314.61 | 50.50 | 0.00 | 0.00 | 22.56 |
Beneish M-Score |
— | — | — | (2.59) | (2.98) | (2.95) | (2.71) | (1.94) | (2.36) | (2.78) |
P/Operating CF |
164.75 | 164.75 | 164.75 | 164.75 | 489.96 | 382.16 | 138.41 | 65.27 | 72.45 | 113.67 |
P/B ratio |
66.90 | 66.90 | 66.90 | 66.90 | 52.65 | 30.09 | 3.69 | 3.45 | 3.06 | 4.39 |
Price to Tangible BV |
153.70 | 153.70 | 153.70 | 153.70 | 108.09 | 53.21 | 5.83 | 5.12 | 4.22 | 8.60 |
EV/Sales |
52.01 | 52.01 | 52.01 | 52.01 | 44.79 | 29.25 | 3.29 | 2.77 | 1.99 | 3.02 |
EV/EBITDA |
127.13 | 127.13 | 127.13 | 127.13 | 114.81 | 188.57 | 41.83 | 64.58 | 79.28 | 30.63 |
EV/Operating CF |
57.70 | 57.70 | 57.70 | 57.70 | 74.71 | 167.87 | 25.07 | (39.33) | (329.00) | 20.75 |
EV/FCF |
57.70 | 57.70 | 57.70 | 57.70 | 79.60 | 312.97 | 45.55 | (34.00) | (184.03) | 21.04 |
Quick Ratio |
0.84 | 1.13 | 1.17 | 0.90 | 3.15 | 4.75 | 3.94 | 3.33 | 3.02 | 2.03 |
Current Ratio |
1.21 | 1.45 | 1.40 | 1.05 | 3.43 | 5.33 | 4.65 | 4.06 | 3.77 | 2.59 |
Net Debt/EBITDA |
(3.29) | 0.96 | (0.18) | (0.25) | (0.64) | (1.55) | (2.36) | (7.12) | (11.48) | (2.21) |
Debt/Assets |
53.16% | 0.00% | 33.99% | 21.90% | 36.27% | 35.46% | 31.33% | 29.91% | 20.60% | 19.61% |
Debt/Equity |
2.45 | 5.10 | 1.18 | 0.48 | 0.83 | 0.73 | 0.65 | 0.63 | 0.37 | 0.35 |
Asset Turnover |
0.10 | 1.62 | 0.82 | 0.75 | 0.63 | 0.49 | 0.50 | 0.55 | 0.69 | 0.84 |
Operating CF/Net income |
0.57 | (0.40) | 1.17 | 1.84 | 2.22 | 2.37 | 1.64 | 1.64 | 0.15 | 19.19 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (4.39) | (1.84) | (0.85) | (0.15) | (0.09) | (0.05) | (0.07) |
Interest Coverage |
(3.80) | 0.00 | 0.00 | — | — | — | — | — | — | — |
| (76.40%) | (380.21%) | 63.57% | 43.08% | 25.11% | 8.50% | 6.88% | (4.98%) | (5.38%) | 1.14% | |
| (11.06%) | (137.67%) | 15.12% | 16.14% | 11.20% | 3.92% | 3.32% | (2.37%) | (2.74%) | 0.63% | |
ROIC |
0.00% | 0.00% | 0.00% | 43.09% | 36.93% | 5.98% | 8.73% | (2.34%) | (3.97%) | 8.27% |
Return on Tangible Assets |
(104.04%) | (213.33%) | 60.60% | 274.83% | 19.01% | 7.41% | 5.99% | (4.25%) | (5.58%) | 1.49% |
Average Days of Receivables |
261.82 | 41.47 | 43.22 | 55.58 | 61.76 | 55.03 | 49.03 | 68.68 | 67.33 | 53.08 |
Research and Development Expense of Revenue |
92.81% | 20.26% | 20.71% | 16.78% | 18.15% | 35.38% | 25.55% | 28.09% | 27.98% | 26.68% |
Selling, General and Administrative Expense of Revenue |
47.74% | 38.55% | 32.50% | 34.80% | 35.67% | 48.48% | 64.11% | 73.34% | 63.75% | 56.08% |
Intangible Assets out of Total Assets |
0.45 | 0.00 | 0.24 | 0.31 | 0.22 | 0.21 | 0.18 | 0.15 | 0.15 | 0.27 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 2.26% | 3.08% | 4.55% | 3.11% | 3.77% | 3.78% | 3.66% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.07 | 0.10 | 0.15 | 0.06 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 1.13 | 0.97 | 3.65 | 0.00 | 0.00 | 1.90 |
Earnings Yield |
1.24% | 1.24% | 1.24% | 1.24% | 1.29% | 1.59% | 1.65% | (1.74%) | (1.79%) | 0.23% |
Free Cash Flow Yield |
1.73% | 1.73% | 1.73% | 1.73% | 1.25% | 0.32% | 1.98% | (2.65%) | (0.47%) | 4.43% |
Revenue per Share |
0.04 | 0.22 | 2.53 | 3.02 | 3.33 | 3.10 | 3.17 | 3.73 | 4.43 | 5.46 |
Operating CF per Share |
(0.03) | 0.07 | 0.55 | 1.19 | 1.31 | 0.59 | 0.35 | (0.26) | (0.03) | 0.79 |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.41) | (0.24) | (0.26) | (0.03) | (0.02) | (0.01) | (0.01) |
Free Cash Flow per Share |
(0.03) | 0.07 | 0.55 | 0.78 | 1.07 | 0.33 | 0.32 | (0.29) | (0.04) | 0.78 |
Cash per Share |
0.08 | 0.14 | 1.50 | 1.19 | 3.24 | 2.99 | 3.20 | 3.25 | 2.50 | 2.61 |
Shareholders Equity per Share |
0.07 | 0.04 | 1.16 | 1.87 | 2.88 | 3.00 | 3.15 | 3.33 | 3.29 | 4.02 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.07 | 0.04 | 1.16 | 1.87 | 2.88 | 3.00 | 3.15 | 3.33 | 3.29 | 4.02 |
Free Cash Flow |
(10.53) | 36.55 | 33.69 | 49.04 | 68.33 | 21.13 | 20.48 | (18.77) | (2.59) | 53.95 |
Working Capital |
11.38 | 33.14 | 37.75 | 5.17 | 186.36 | 202.67 | 217.80 | 238.37 | 204.64 | 183.68 |
Capital Expenditures |
(1.59) | (7.28) | (4.33) | (25.44) | (15.30) | (16.72) | (1.98) | (1.46) | (0.80) | (0.75) |
Net Current Asset Value |
(39.08) | (74.49) | (42.96) | (19.07) | 28.19 | 45.05 | 56.34 | 72.27 | 99.52 | 76.61 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.77 | 0.00 | 0.00 | 43.93 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.13 | 0.07 | 0.08 | 0.01 | 0.01 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.72 | 0.00 | 0.00 | 47.10 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.13 | 0.41 | 0.47 | 0.61 | 0.68 | 1.48 | 1.27 | 1.64 | 2.07 | 1.55 |
Cash ROIC |
(7.89%) | 19.32% | 13.63% | 19.82% | 12.62% | 4.02% | 3.75% | (3.29%) | (0.55%) | 9.72% |
Accounts Receivable Turnover |
1.38 | 8.90 | 10.13 | 8.02 | 6.56 | 6.04 | 7.14 | 6.65 | 5.89 | 6.87 |
Accounts Payable Turnover |
0.66 | 2.20 | 3.14 | 0.99 | 0.53 | 0.47 | 0.36 | 0.40 | 0.51 | 0.53 |
Inventory Turnover |
0.28 | 0.93 | 1.42 | 1.32 | 1.26 | 0.87 | 0.50 | 0.51 | 0.63 | 0.75 |
Average Days of Payables |
379.29 | 217.97 | 93.51 | 619.53 | 739.12 | 733.26 | 1,131.97 | 1,050.00 | 686.83 | 849.52 |
Days of Inventory on Hand |
1,203.98 | 423.78 | 243.78 | 247.27 | 328.06 | 471.49 | 879.68 | 821.73 | 574.57 | 520.64 |
Average Receivables |
12.13 | 12.13 | 15.33 | 23.61 | 32.36 | 32.94 | 28.80 | 36.89 | 50.49 | 54.76 |
Average Payables |
8.66 | 8.66 | 9.50 | 24.12 | 44.13 | 45.07 | 48.47 | 63.50 | 69.57 | 86.26 |
Average Inventory |
20.49 | 20.49 | 21.00 | 18.05 | 18.68 | 24.23 | 34.82 | 49.54 | 56.24 | 60.31 |
Average Assets |
166.84 | 66.73 | 190.04 | 251.11 | 337.02 | 407.88 | 411.56 | 444.33 | 431.42 | 449.97 |
Average Common Equity |
24.16 | 24.16 | 45.19 | 94.11 | 150.34 | 188.18 | 198.78 | 211.71 | 219.92 | 249.08 |
Columns are period end dates · fundamentals updated 2 Nov 2026